Strategic Analysis and Planning for Novartis Pharmaceutical Industry

This presentation provides a comprehensive strategic analysis of the Novartis Pharmaceutical industry. It begins with an introduction to strategic control and its importance in business planning. The analysis utilizes SWOT (Strengths, Weaknesses, Opportunities, and Threats) to evaluate the company's internal and external environments. Key aspects include competitive pressures, government policies, and internal operational efficiencies. Furthermore, the presentation includes a value chain analysis of Novartis, examining primary activities such as inbound and outbound logistics, operations, and its impact on consumer satisfaction. The analysis also highlights the company’s mergers and acquisitions track record. Overall, the presentation aims to provide a detailed overview of Novartis's strategic position and its potential for future growth, which is a valuable resource for students on Desklib.

POSTER PRESENTATION

Poster presentation
INTRODUCTION
Strategic control refers to process used by various
organizations for controlling the formation and execution of
business plans. It is specialized management control system
which is different other forms of management control system.
There are various strategic control systems and analytical
tools for assessing the business issues and framing strategies
for overcoming those problems.
Situational Analysis
Company – For analyzing the internal condition of the
company TOWS have been used.
Threats - Pharma industry is facing high competitions in
the market that is making difficult for the companies to
operate smoothly. So this can overcome the
opportunities of company to grow. It can also give their
subsidies the power of hampering the companies growth.
If competition increases the license permitted by
government can also be weaken. These can act as threat
for company.
Opportunities- Liberal government policies will create
opportunities for producing new products in market.
Government is giving subsidies for carrying research
and development for new medicines. Relief in licensing
of hospital will create demand for pharma products.
Weaknesses: Novartis is not able to manage its operation
effectively for manufacturing the products that increases
costing. Not having enough resources to carry out
research and development for inventing new products.
Company is not having strong promotional strategies for
increasing the recognition of the brand in the society.
This can overcome the strength they can hamper the
culture of company.
Strength: Strong dealer community – It has built a
culture among distributor & dealers where the dealers
not only promote company’s products but also invest in
training the sales team to explain to the customer how
he/she can extract the maximum benefits out of the
products.
Successful track record of integrating complimentary
firms through mergers & acquisition.
Value chain analysis of Novartis pharmaceutical industry
Company is engage in manufacturing drugs like Clozapine
Primary activities- Company makes sure that the Clozapine
has been deliver to consumers at timely basis.
Inbound logistics- They make sure that the Clozapine which
are being deliver are effective and efficient.
Operations- Firm has been engage in making efficient use of
resources which also reduces the waste.
Outbound Logistics- In this company make sure that the
wholesalers and retailers deliver the best quality of Clozapine
to consumers that can help company in growing and also
attracting more consumers.